Silence Therapeutics Plc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Silence Therapeutics Plc - overview
Established
1999
Location
London, -, UK
Primary Industry
Biotechnology
About
Silence Therapeutics Plc is a biotechnology company that develops precision-engineered medicines focused on siRNA therapeutics to silence disease-associated genes, addressing significant unmet medical needs across various diseases. Founded in 1999 and headquartered in London, UK, Silence Therapeutics Plc specializes in precision-engineered medicines, primarily through its proprietary mRNAi GOLD™ platform. The company has undergone strategic pivots, including a reverse takeover of SR Pharma in July 2005, which facilitated its listing on London's AIM. Craig Tooman serves as the CEO, leading the company to a total of 10 deals, with its most recent funding round, PIPE, raising USD 20.
00 mn, bringing the total amount raised to USD 20. 00 mn. Silence Therapeutics specializes in precision-engineered medicines, focusing on the development of siRNA (short interfering RNA) therapeutics through their proprietary mRNAi GOLD™ platform. This platform aims to target and silence disease-associated genes, providing treatment solutions for hematology, cardiovascular diseases, and rare conditions.
The company extends its offerings to regions including North America, Europe, and Asia, thereby addressing significant medical needs in these diverse markets. In 2023, Silence Therapeutics reported revenue of USD 31. 56 mn and an EBITDA of USD -61. 08 mn.
Revenue is generated through strategic partnerships and collaborations with pharmaceutical companies and research institutions for the co-development and licensing of their siRNA therapeutics, although specific pricing structures are not disclosed. Silence Therapeutics plans to capitalize on the recent funding raised in July 2005 to support its growth initiatives, including the development of new siRNA therapeutics targeting various disease areas. The company aims to expand its market presence in North America and Europe, while also exploring opportunities in Asia. Specific product launches and market entries are expected to be outlined in their future strategic plans.
Current Investors
MPM BioImpact, Apax Partners, Frazier Healthcare Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.silence-therapeutics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.